RecruitingPhase 4NCT07406139

PCC Treatment for Hemophilia Patients With Inhibitor（2022PCC-A）

Studying Hemophilia

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Intervention
PCC(drug)
Enrollment
30 enrolled
Eligibility
12-65 years · All sexes
Timeline
2026 – 2026

Study locations (1)

Collaborators

North China University of Science and Technology · The Second Affiliated Hospital of Kunming Medical University · The Second People's Hospital of Anhui Province · Children's Hospital of Chongqing Medical University · Union Hospital, Affiliated to Fujian Medical University · The First Affiliated Hospital of Xiamen University · First Affiliated Hospital of Guangxi Medical University

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07406139 on ClinicalTrials.gov

Other trials for Hemophilia

Additional recruiting or active studies for the same condition.

See all trials for Hemophilia →

← Back to all trials